ViiV Healthcare’s long-acting HIV treatment Cabenuva (cabotegravir + rilpivirine) meets primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia

Data ReadoutpositiveCabenuvaPositive

AI Analysis

Summary

ViiV Healthcare's Cabenuva (cabotegravir + rilpivirine) met its primary endpoint by demonstrating superior viral suppression compared to daily oral therapy in people with viremia. This positive data readout represents significant progress for the long-acting HIV treatment candidate.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Met primary endpoint of superior viral suppression vs. daily oral therapy in people with viremia

Importance:7/10

Sentiment:

0.85

HIVlong-acting therapyviral suppressionclinical trial

Related Companies

$GSK

Read the original article

Published by yahoo_finance on October 6, 2026 1:00 PM

Read Original